Latest INFO CENTER

FDA Approves Abilify Maintena for Schizophrenia

The US Food and Drug Administration (FDA) has approved ABILIFY MAINTENA™ (aripiprazole) for extended release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

FDA Approves Adasuve for Agitation with Schizophrenia, Bipolar I

Alexza Pharmaceuticals, Inc. announced today that the US Food and Drug Administration (FDA) approved Adasuve (loxapine) Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Merck Announces New Phase III Data for Suvorexant

Merck, known as MSD outside the United States and Canada, announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia.

Merck Drug for Insomnia

Merck, known as MSD outside the United States and Canada, provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if approved, will be a new mechanism for the treatment of insomnia.

This Mama's Smokin'

Maternal cigarette smoking in the first trimester was associated with a 20 to 70 percent greater likelihood that a baby would be born with certain types of congenital heart defects, according to a study by the Centers for Disease Control and Prevention.

This is Your Brain on Drugs

People with addictions to stimulants tend to choose instant gratification or a smaller but sooner reward over a future benefit, even if the future reward is greater.

End Addiction with a Vaccine?

Researchers have produced a lasting anti-cocaine immunity in mice by giving them a safe vaccine that combines bits of the common cold virus with a particle that mimics cocaine.

A Plan to Help the Pre-existing Condition Crowd

The U.S. Department of Health and Human Services (HHS) is increasing awareness about a health plan for uninsured Americans with pre-existing conditions created by the Affordable Care Act.